BlueSphere Bio, Inc
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation (NCT07566585) | BlueSphere Bio, Inc | 2026-04-21 |
| BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS (NCT06704152) | BlueSphere Bio, Inc | 2025-02-04 |
Track BlueSphere Bio, Inc automatically
Every clearance here is in the API, with alerts when new ones post.